With RSD to Turkey – one of the most popular study-travel destinations worldwide
11.7.2024 10:53:41 CEST | news aktuell GmbH | Press release
Unique antique ruins and expansive beaches by the glittering sea, picturesque old towns and great hospitality: This and much more is what Turkey offers. A truly wonderful travel destination. And from the beginning, one of the most important pillars in the broad portfolio of study tours offered by RSD Travel Ltd..
Despite the Corona crisis, demand for Turkish tours has surged once again due to their high-quality offerings and value for money. Over half a million RSD clients have already enjoyed memorable holidays, discovering Turkey's natural and cultural diversity while staying in star-rated hotels – sometimes even with private beach.
RSD owes its high customer satisfaction in Turkey to its professional team, who know the country by heart. There is a lot of praise for this - for example from Professor Nevzat Cevik, one of the most well-known excavation directors of ancient sites in the country: "Thank you for making our well-preserved historical treasures, our breathtaking landscapes and our fascinating history come alive for a broad, interested educated class!". The 15-day Cappadocia 5-star trip, for instance, allows guests to witness the incredible Monk's Valley, a UNESCO World Heritage Site, and explore the vibrant Antalya along the Mediterranean.
During the two-week exclusive Lycia trip, guests can traverse the important ruins of Ephesus, marvel at Pamukkale's unique limestone terraces, and the Temple of Artemis - one of the seven wonders of the ancient world. Through an Istanbul & Aegean combo package, visitors can explore the grandeur of Istanbul, including the world-renowned Hagia Sophia, the old town - a UNESCO World Heritage Site, and the luxurious Topkapi Palace, once the government seat of the Ottoman Sultans.
Towcester
Phone: + 44 20 3514 35 43
e-mail: info@rsd-travel.co.uk
Images
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Vyoma awarded ESA data procurement contract for space-based data on small space debris24.2.2026 10:53:34 CET | Press release
(Munich, February 24th, 2026) Vyoma, a Munich-based company providing Space Domain Awareness (SDA) capabilities, has been selected as the winner of the ESA tender on ”Data Procurement for Space-Based Statistical Data on Small Space Debris Phase 1”, funded via ESA‘s Space Safety Programme (S2P). ESA’s Meteoroid And Space debris Terrestrial Environment Reference (MASTER) model provides a description of the space environment around Earth, supporting satellite designers, operators and others with risk assessments. Currently, there exists a significant temporal and spatial knowledge gap for observations of space debris with sizes smaller than the detection limit of ground-based sensors. Vyoma's Flamingo-1 satellite is ideally positioned to generate the image data ESA is seeking. Flying “in-situ” at an altitude of 510 km, Flamingo-1's instrument can monitor large volumes of space at once. This sensor detects objects at long and short distances and captures small and fast objects reliably, im
Medi-Globe Launches mAI Companion® — the World’s First Real Time AI Assistant for Pancreatic EUS, Co Developed with IHU Strasbourg —Now MDR CE Marked and Available for Clinical Use in Europe24.2.2026 10:00:00 CET | Press release
Rohrdorf (Achenmühle), Germany — February 24, 2026 — Medi-Globe today announced the launch of mAI Companion®, a real-time medical AI solution designed to assist physicians in detecting pancreatic lesions during endoscopic ultrasound (EUS) — addressing one of the deadliest and most difficult-to-detect cancers, where earlier identification can dramatically change patient outcomes.
Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect24.2.2026 08:43:52 CET | Press release
Aachen, Germany & Victoria, Australia, 24 February 2026 – Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a topical, non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain. Under the agreement, Clinect will be responsible for obtaining marketing authorisation for Qutenza® in Australia and, upon approval, marketing and distributing the product in Australia.
Clean energy needs a clean planet: PLAN-B NET ZERO and everwave launch joint initiative20.2.2026 13:26:02 CET | Press release
(Berlin, Germany) A strong start to 2026. PLAN-B NET ZERO enters into a partnership with the Aachen-based environmental scale-up everwave. With the guiding principle ‘1 euro = 1 kilogram of waste’, the partners recovered 10,000 kilograms of waste from rivers in Cambodia at the start of the initiative Around 11 million tonnes of plastic waste enter the oceans every year. Without effective countermeasures, this volume could almost triple by 2040. Studies show that about 80 percent of marine plastic reaches the sea via roughly 1,656 rivers worldwide. To date, everwave has removed more than 2.4 million kilograms of plastic from rivers in Cambodia, Albania, and Thailand. The company uses waste collection boats, barriers, and manual cleanups to stop plastic before it reaches the oceans. At the same time, mobile sorting and recycling solutions return materials efficiently to the circular economy. AI support optimizes collection routes to clean as many waterways as possible in a sustainable wa
Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development18.2.2026 11:52:51 CET | Press release
Aachen, Germany, 18 February 2026 – Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in the second half of 2026.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom